Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Marta Colaneri, Teresa Chiara Pieri, Silvia Roda, Alessandra Ricciardi, Manuel Gotti, Jacqueline Ferrari, Luca Arcaini, Sara Rattotti, Antonio Piralla, Federica Giardina, Guglielmo Ferrari, Paolo Sacchi, Valentina Zuccaro, Fausto Baldanti, Raffaele Bruno
Early therapies to prevent severe COVID-19 have an unclear impact on patients with hematological malignancies. The aim of this study was to assess their efficacy in this group of high-risk patients with COVID-19 in preventing hospitalizations and reducing the SARS-CoV-2 shedding. This was a single-center, retrospective, observational study conducted in the Fondazione IRCSS Policlinico San Matteo of Pavia, Northern Italy. We extracted the data of patients with hematologic malignancies and COVID-19 who received and did not receive early COVID-19 treatment between 23 December 2021, and May 2022...
December 15, 2022: Journal of Clinical Medicine
#22
E Zucca, L Arcaini, C Buske, P W Johnson, M Ponzoni, M Raderer, U Ricardi, A Salar, K Stamatopoulos, C Thieblemont, A Wotherspoon, M Ladetto
No abstract text is available yet for this article.
December 16, 2022: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#23
JOURNAL ARTICLE
Michele Merli, Luca Arcaini
Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas and include 3 different subtypes-namely, extranodal (EMZL), nodal, and splenic (SMZL). The initial assessment requires specific diagnostic and staging procedures depending on organ-related peculiarities. In particular, although positron emission tomography/computed tomography was not initially recommended, recent data have reassessed its role in the routine staging of MZL, especially when only localized treatment is planned or there is a suspicion of histologic transformation...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
#24
JOURNAL ARTICLE
Christian Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, Amandine Tisserand, Gaëlle Vertenoeil, Audrey Nédélec, Didier Vertommen, Anita Roy, Caroline Marty, Harini Nivarthi, Jean-Philippe Defour, Mira El-Khoury, Eva Hug, Andrea Majoros, Erica Xu, Oleh Zagrijtschuk, Tudor Emanuel Fertig, Daciana S Marta, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Carola Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Roman Lesyk, Veronika Buxhofer-Ausch, Sonja Heibl, Florence Pasquier, Isabelle Plo, William Vainchenker, Robert Kralovics, Stefan N Constantinescu
Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino-acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact with and activate the thrombopoietin receptor (TpoR/MPL) in the same cell. We report that mutant CALR proteins are secreted and can be found in patient plasma at levels up to 160ng/mL, with a mean of 25.64ng/mL. Plasma mutant CALR is found in complex with soluble Transferrin Receptor 1 (sTFRC) that acts as a carrier protein and increases CALR mutant half-life...
November 10, 2022: Blood
#25
JOURNAL ARTICLE
Michele Merli, Isacco Ferrarini, Francesco Merli, Alessandro Busca, Roberto Mina, Brunangelo Falini, Riccardo Bruna, Roberto Cairoli, Monia Marchetti, Alessandra Romano, Michele Cavo, Luca Arcaini, Livio Trentin, Chiara Cattaneo, Enrico Derenzini, Nicola Stefano Fracchiolla, Francesco Marchesi, Annamaria Scattolin, Atto Billio, Monica Bocchia, Massimo Massaia, Carlo Gambacorti-Passerini, Francesca Romana Mauro, Massimo Gentile, Sara Mohamed, Matteo Giovanni Della Porta, Elisa Coviello, Daniela Cilloni, Giuseppe Visani, Augusto Bramante Federici, Maria Chiara Tisi, Laura Cudillo, Sara Galimberti, Filippo Gherlinzoni, Livio Pagano, Anna Guidetti, Lorenza Bertù, Paolo Corradini, Francesco Passamonti, Carlo Visco
COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between February 25, 2020 and February 1, 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n=127) had received at least one line of therapy for CLL, including 108 (83...
October 20, 2022: Hematological Oncology
#26
JOURNAL ARTICLE
Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Cafro, Renato Zambello, Laura Paris, Gregorio Barilà, Cecilia Olivares, Alessandra Pompa, Rita Mazza, Francesca Farina, Martina Soldarini, Pietro Benvenuti, Giuseppina Pagani, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Catherine Klersy, Luca Arcaini, Maria Teresa Petrucci
Lenalidomide and dexamethasone (Rd)-based triplets, in particular Carfilzomib-Rd (KRd) and Daratumumab-Rd (DaraRd), represent a standard of care in lenalidomide sensitive multiple myeloma (MM) patients in first relapse. Meta-analysis of randomized clinical trials (RCT), suggested better outcome with DaraRd. Trying to address this issue in clinical practice, we collected data of 430 consecutive MM patients addressed to Rd-based triplets in first relapse between January 2017 and March 2021. Overall, the most common used regimen was DaraRd, chosen in almost half of the cases (54...
October 6, 2022: Haematologica
#27
MULTICENTER STUDY
Richard Greil, Katerina Kopeckova, Luca Arcaini, Aasim Amin, Katrien de Graaf, Anna-Maria Jegg
CONTEXT: The chemo-free immunotherapy tafasitamab + lenalidomide has been granted FDA accelerated approval and EU conditional marketing authorization for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in autologous stem cell transplant-ineligible adults. Treatment schedule optimization aims to reduce the frequency of hospital visits and decrease treatment burden and healthcare utilization. MINDway (NCT05222555) will investigate if tafasitamab administration at levels higher than the approved 12 mg/kg dose at a reduced dosing frequency maintains the benefit-risk relationship of tafasitamab + lenalidomide for patients with R/R DLBCL...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
#28
JOURNAL ARTICLE
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, Elisa Rumi, Margherita Maffioli, Francesca Palandri, Valerio De Stefano, Marianna Caramella, Silvia Salmoiraghi, Jean-Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Marco Ruggeri, Richard T Silver, Francesco Albano, Giulia Benevolo, David M Ross, Matteo G Della Porta, Timothy Devos, Giada Rotunno, Rami S Komrokji, Ilaria C Casetti, Michele Merli, Marco Brociner, Domenica Caramazza, Giuseppe Auteri, Tiziano Barbui, Daniele Cattaneo, Lorenza Bertù, Luca Arcaini, Alessandro M Vannucchi, Francesco Passamonti
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (primary MF, PMF), while yet not recognized in post PV/ET-MF (known as secondary MF, SMF). Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10.7%) developed a TE at a median follow-up of 3.5 years (range, 1-21.4), with an incidence of 2.3% patients per year...
October 2022: Leukemia
#29
Arturo Bonometti, Nicola Aronico, Giovanni Santacroce, Sara Fraticelli, Marco Lucioni, Claudio Salvatore Cartia, Alessandro Vanoli, Mario Andrea Latorre, Luca Arcaini, Marco Paulli, Antonio Di Sabatino
Gastrointestinal (GI) involvement of plasma cell neoplasms is extremely rare. Herein, we describe the case of a 74-year-old Caucasian woman who came to our attention with abdominal pain, food vomiting, and weight loss of 10 kg over 1 year. A computed tomography scan of the abdomen revealed circumferential thickening of terminal ileum, for which the patient underwent an urgent 20-cm-long ileal resection. Histopathological and immunophenotypic analysis revealed a plasma cell neoplasm of the ileum. Subsequent investigations found a serum monoclonal immunoglobulin A component, an osteolytic lesion of the left jaw, and a clonal bone marrow plasma cell infiltrate carrying 1q21 amplification...
2022: Frontiers in Oncology
#30
JOURNAL ARTICLE
Sara Steffanoni, Teresa Calimeri, Alice Laurenge, Christopher P Fox, Carole Soussain, Christian Grommes, Maria Chiara Tisi, Jesca Boot, Nicola Crosbie, Carlo Visco, Luca Arcaini, Sridhar Chaganti, Marianna C Sassone, Alvaro Alencar, Daniele Armiento, Ilaria Romano, Jorg Dietrich, Gilad Itchaki, Riccardo Bruna, Nicola S Fracchiolla, Laura Arletti, Adriano Venditti, Stephen Booth, Pellegrino Musto, Khê Hoang Xuan, Tracy T Batchelor, Kate Cwynarski, Andrés J M Ferreri
To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six...
August 9, 2022: British Journal of Haematology
#31
JOURNAL ARTICLE
Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi Mv, Guidetti A, Marchetti M, Massaia M, Arcaini L, Krampera M, Mohamed S, Gherlinzoni F, Mecucci C, Gentile M, Romano I, Venditti A, Ruggeri M, Ferrero D, Coviello E, Fabbri E, Corradini P, Passamonti F
A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls...
August 6, 2022: Hematological Oncology
#32
JOURNAL ARTICLE
Patrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, Roberto Mina, Andrés José María Ferreri, Francesco Merli, Margherita Oberti, Mauro Krampera, Alessandra Romano, Caterina Zerbi, Jacqueline Ferrari, Michele Cavo, Marco Salvini, Lorenza Bertù, Nicola Stefano Fracchiolla, Francesco Marchesi, Massimo Massaia, Vincenzo Marasco, Roberto Cairoli, Anna Maria Scattolin, Alessandro Maria Vannucchi, Carlo Gambacorti-Passerini, Pellegrino Musto, Filippo Gherlinzoni, Antonio Cuneo, Antonello Pinto, Livio Trentin, Monica Bocchia, Sara Galimberti, Elisa Coviello, Maria Chiara Tisi, Alessandro Morotti, Brunangelo Falini, Mauro Turrini, Agostino Tafuri, Atto Billio, Massimo Gentile, Roberto Massimo Lemoli, Adriano Venditti, Matteo Giovanni Della Porta, Francesco Lanza, Luigi Rigacci, Patrizia Tosi, Sara Mohamed, Alessandro Corso, Mario Luppi, Nicola Giuliani, Alessandro Busca, Livio Pagano, Raffaele Bruno, Paolo Antonio Grossi, Paolo Corradini, Francesco Passamonti, Luca Arcaini
The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14...
July 19, 2022: Hematological Oncology
#33
JOURNAL ARTICLE
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie-Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig
BACKGROUND: Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies. AIMS: Phase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, combined with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL)...
July 19, 2022: Cancer reports
#34
JOURNAL ARTICLE
Daniele Vanni, Oscar Borsani, Yasuhito Nannya, Emanuela Sant'Antonio, Chiara Trotti, Ilaria Carola Casetti, Daniela Pietra, Anna Gallì, Silvia Zibellini, Virginia Valeria Ferretti, Luca Malcovati, Seishi Ogawa, Luca Arcaini, Elisa Rumi
In a cohort of 3131 patients with myeloproliferative neoplasms (MPNs), we identified 200 patients (6.4%) who reported a second case of haematological malignancies (HM) in first- or second-degree relatives. The occurrence of a second HM in the family was not influenced by MPN subtype, sex or driver mutation, while it was associated with age at MPN diagnosis: 8.5% of patients diagnosed with MPN younger than 45 years had a second relative affected with HM compared to 5.5% of those diagnosed at the age of 45 years or older ( p = 0...
May 2022: EJHaem
#35
MULTICENTER STUDY
Michele Merli, Sara Rattotti, Michele Spina, Francesca Re, Marina Motta, Francesco Piazza, Lorella Orsucci, Andrés J M Ferreri, Omar Perbellini, Anna Dodero, Daniele Vallisa, Alessandro Pulsoni, Armando Santoro, Paolo Sacchi, Valentina Zuccaro, Emanuela Chimienti, Filomena Russo, Carlo Visco, Anna Linda Zignego, Luigi Marcheselli, Francesco Passamonti, Stefano Luminari, Marco Paulli, Raffaele Bruno, Luca Arcaini
PURPOSE: We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far. METHODS: FIL_BArT is a prospective, multicenter, phase II trial that evaluated genotype-appropriate DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conventional antilymphoma treatment...
December 10, 2022: Journal of Clinical Oncology
#36
JOURNAL ARTICLE
Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, Valerio Zoli, Benedetta Puccini, Andrea Evangelista, Luca Arcaini, Leonardo Flenghi, Carlo Visco, Michael Mian, Alice Di Rocco, Claudia Peracchio, Manuel Gotti, Maria Chiara Tisi, Francesca Palombi, Samantha Pozzi, Daniela Gioia, Piera Viero, Maurizio Martelli
Salvage immunochemotherapy and transplant consolidation is the standard treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We tested a combination of Obinutuzumab and DHAP for treating R/R DLBCL. The primary end point was the rate of complete metabolic response (CMR). Secondary end points were stem cell mobilization, stem cell engraftment, overall survival, and feasibility. In this prospective, phase-2, single-arm trial (EudraCT 2014-004014-17) patients received the standard three doses of Obinutuzumab for the first cycle, and then one dose...
October 2022: Hematological Oncology
#37
JOURNAL ARTICLE
Alice Nevone, Maria Girelli, Silvia Mangiacavalli, Bruno Paiva, Paolo Milani, Pasquale Cascino, Maggie Piscitelli, Valentina Speranzini, Claudio Salvatore Cartia, Pietro Benvenuti, Ibai Goicoechea, Francesca Fazio, Marco Basset, Andrea Foli, Martina Nanci, Giulia Mazzini, Serena Caminito, Melania Antonietta Sesta, Simona Casarini, Paola Rognoni, Francesca Lavatelli, Maria Teresa Petrucci, Pier Paolo Olimpieri, Stefano Ricagno, Luca Arcaini, Giampaolo Merlini, Giovanni Palladini, Mario Nuvolone
Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC). The pathogenicity of LCs is encrypted in their sequence, yet molecular determinants of amyloidogenesis are poorly understood. Higher rates of N-glycosylation among clonal κ LCs from patients with AL amyloidosis compared to other monoclonal gammopathies indicate that this post-translational modification is associated with a higher risk of developing AL amyloidosis...
August 2022: Leukemia
#38
JOURNAL ARTICLE
Laura Gragnani, Serena Lorini, Silvia Marri, Sara Rattotti, Francesco Madia, Silvia Zibellini, Monica Monti, Umberto Basile, Enrico Di Stasio, Massimo Libra, Luca Arcaini, Anna Linda Zignego
Cryoglobulinemic Vasculitis (CV) is an autoimmune/lymphoproliferative disorder associated with HCV infection that in 5%-10% of cases evolves into a B cell Non-Hodgkin's Lymphoma (NHL). B-cell activating factor (BAFF) is a key regulator in B-cell development and survival. Particular genetic variants are responsible for BAFF signaling impairment in autoimmune and neoplastic diseases. We evaluated BAFF and BAFF-receptor (BAFF-R) polymorphisms in order to determine if they predispose to HCV-related CV and NHL. The analysis was performed on 416 HCV-chronically infected patients: 136 HCV without signs/symptoms of lymphoproliferations/autoimmunity (HCV), 166 HCV with CV (HCV-CV) and 114 HCV with NHL (HCV-NHL)...
October 2022: Hematological Oncology
#39
JOURNAL ARTICLE
Mario Petrini, Gianluca Gaidano, Andrea Mengarelli, Ugo Consoli, Armando Santoro, Anna Maria Liberati, Marco Ladetto, Vincenzo Fraticelli, Attilio Guarini, Donato Mannina, Paola Ferrando, Paolo Corradini, Pellegrino Musto, Caterina Stelitano, Dario Marino, Andrea Camera, Marco Murineddu, Roberta Battistini, Giuseppe Caparrotti, Mauro Turrini, Luca Arcaini, Simone Santini, Manuela Cerqueti, Andres J M Ferreri, Nicola Cantore, Alessandro Inzoli, Giovanni Cardinale, Benedetto Ronci, Giorgio La Nasa, Stefano Massimi, Gianfranco Gaglione, Valentina Barbiero, Maurizio Martelli
Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included adult patients with CD20+ DLBCL or FL having received at least one full dose of IV RTX 375 mg/m2 during induction or maintenance. Patients on induction received ≥4 cycles of RTX SC 1400 mg plus standard chemotherapy and FL patients on maintenance received ≥6 cycles of RTX SC...
2022: Advances in Hematology
#40
JOURNAL ARTICLE
Oscar Borsani, Paul Bastard, Jérémie Rosain, Adrian Gervais, Emanuela Sant'Antonio, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Chiara Trotti, Silvia Catricalà, Virginia Valeria Ferretti, Luca Malcovati, Luca Arcaini, Jean-Laurent Casanova, Alessandro Borghesi, Elisa Rumi
No abstract text is available yet for this article.
January 31, 2022: Blood
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
